Glaucoma Market Report 2026

Glaucoma Market Overview

• Glaucoma market size has reached to $8.2 billion in 2025 • Expected to grow to $10.62 billion in 2030 at a compound annual growth rate (CAGR) of 5.3% • Growth Driver: Impact Of Rising Chronic Eye Conditions On Vision Loss And Treatment Demand • Market Trend: Innovative Approaches To Glaucoma Treatment With Dual Mechanism Therapies • North America was the largest region in 2025 and Asia-Pacific is the fastest growing region.

What Is Covered Under Glaucoma Market?

Glaucoma is a group of eye disorders that cause damage to the optic nerve, typically resulting from increased intraocular pressure (IOP). This damage can lead to progressive, irreversible vision loss if untreated, making glaucoma one of the leading causes of blindness worldwide. Glaucoma is a leading cause of blindness worldwide, and early detection through regular eye exams is critical to prevent vision loss. The main types of glaucoma diseases are open-angle glaucoma, angle-closure glaucoma, and others. Open-angle glaucoma is a type of glaucoma where the eye's drainage angle remains open, but the trabecular meshwork becomes gradually blocked, leading to increased intraocular pressure (IOP). It can be diagnosed using tonometry, ophthalmoscopy, perimetry, and gonioscopy, and it offers various drug classes such as beta-blockers, prostaglandins, alpha-adrenergic agonists, carbonic anhydrase inhibitors, combination drugs, and others. It is administered orally, by injection, intravitreally, and by other routes and is used by hospitals, ophthalmic clinics, and ambulatory surgical centers.

What Is The Glaucoma Market Growth Forecast?

The glaucoma market size is expected to see strong growth in the next few years. It will grow to $10.62 billion in 2030 at a compound annual growth rate (CAGR) of 5.3%. The growth in the forecast period can be attributed to technological advancements in imaging, expansion of surgical innovations, digital eye health monitoring, early detection initiatives, rising ophthalmology investments. Major trends in the forecast period include rising adoption of early diagnostic screening, increased use of combination drug therapies, growth of minimally invasive glaucoma surgery, expansion of home-based eye monitoring, improved patient awareness programs.

Global Glaucoma Market Segmentation

1) By Disease Type: Open Angle Glaucoma, Angle Closure Glaucoma, Other Disease Types 2) By Diagnosis: Tonometry, Ophthalmoscopy, Perimetry, Gonioscopy 3) By Drug Class: Beta Blockers, Prostaglandins, Alpha Adrenergic Agonist, Carbonic Anhydrase Inhibitors, Combination Drugs, Other Drug Classes 4) By Administration: Oral, Injections, Intravitreal, Other Administrations 5) By End-User: Hospitals, Ophthalmic Clinics, Ambulatory Surgical Centers Subsegments: 1) By Open Angle Glaucoma: Primary Open Angle Glaucoma (POAG), Secondary Open Angle Glaucoma 2) By Angle Closure Glaucoma: Primary Angle Closure Glaucoma, Secondary Angle Closure Glaucoma 3) By Other Disease Types: Normal-Tension Glaucoma, Pigmentary Glaucoma, Pseudoexfoliative Glaucoma, Congenital Glaucoma

What Is The Driver Of The Glaucoma Market?

The rising prevalence of chronic eye conditions is expected to propel the growth of the glaucoma market going forward. Chronic eye conditions are long-term disorders that affect the eyes, often causing persistent vision impairment or discomfort and requiring ongoing management or treatment. Chronic eye conditions are rising due to aging populations, increased screen time, lifestyle factors, and a higher prevalence of conditions like diabetes and hypertension. Glaucoma treatment is required for chronic eye conditions to lower intraocular pressure, prevent further optic nerve damage, and preserve vision, as untreated glaucoma can lead to irreversible blindness. For instance, in December 2024, according to the National Health Service (NHS), a UK-based publicly funded healthcare system, over 2 million people in the UK are living with sight loss in 2024. Further, the number of people living with sight loss is projected to increase by 27%, reaching approximately 2.8 million by 2035. Therefore, the rising prevalence of chronic eye conditions is driving the glaucoma industry.

Key Players In The Global Glaucoma Market

Major companies operating in the glaucoma market are Roche Holding AG, Merck & Co. Inc., AbbVie Inc., Novartis AG, Teva Pharmaceuticals Industries Ltd., Otsuka Pharmaceutical Co. Ltd., Sun Pharmaceutical Industries Ltd., Cipla Limited, Bausch & Lomb Corp., Carl Zeiss Meditec, Santen Pharmaceuticals Co. Ltd., Topcon Corporation, Thea Laboratoires, Corza Ophthalmology, Lumenis Ltd., Alcon Inc., Glaukos Corporation, Iridex Corporation, Nova Eye Medical Ltd., Nidek Co. Ltd., Haag-Streit AG

Global Glaucoma Market Trends and Insights

Major companies operating in the glaucoma market are focusing on developing innovative therapies, such as Rho-kinase (ROCK) inhibitors, to offer a dual mechanism of action, reducing intraocular pressure through both enhanced outflow of aqueous humor and the relaxation of trabecular meshwork cells, making them effective in treating glaucoma. Rho-kinase (ROCK) inhibitors are a class of drugs that target and block the activity of Rho-kinase enzymes, which regulate cell contraction and treat glaucoma to reduce intraocular pressure. For instance, in July 2023, Santen Pharmaceutical Co. Ltd., a Japan-based eye care products company, launched Roclanda in the UK. Roclanda is a fixed-dose combination (FDC) of latanoprost and netarsudil, a novel Rho-kinase (ROCK) inhibitor, that effectively reduces intraocular pressure (IOP) by targeting trabecular meshwork dysfunction. It is indicated for adult patients with primary open-angle glaucoma or ocular hypertension who have not achieved adequate IOP reduction with monotherapy using a prostaglandin or netarsudil. The introduction of Roclanda in Europe marks the first new class of glaucoma medication in 25 years, offering a breakthrough in treatment. By combining netarsudil and latanoprost, Roclanda works synergistically to increase outflow through trabecular (conventional) and uveoscleral (unconventional) pathways, providing a comprehensive approach to managing elevated IOP.

What Are Latest Mergers And Acquisitions In The Glaucoma Market?

In December 2024, Bausch + Lomb Corp., a Canada-based healthcare company, acquired Elios Vision Inc. for an undisclosed amount. The acquisition opens new possibilities for more effective glaucoma treatment without needing implants, enhancing the company's ability to offer comprehensive solutions. It also underscores the company's commitment to investing in technologies that empower eye care professionals to better meet their patients' evolving needs. Elios Vision Inc. is a US-based developer of minimally invasive glaucoma surgery (MIGS) procedures.

Regional Outlook

North America was the largest region in the glaucoma market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in this market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in this market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

What Defines the Glaucoma Market?

The glaucoma market consists of revenues earned by entities by providing services such as surgical services, telemedicine consultations, treatment monitoring and custom surgical planning. The market value includes the value of related goods sold by the service provider or included within the service offering. The glaucoma market also includes sales of laser treatment devices, glaucoma drainage implants, visual field analyzers and surgical tools. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

How is Market Value Defined and Measured?

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

What Key Data and Analysis Are Included in the Glaucoma Market Report 2026?

The glaucoma market research report is one of a series of new reports from The Business Research Company that provides market statistics, including industry global market size, regional shares, competitors with the market share, detailed market segments, market trends and opportunities, and any further data you may need to thrive in the glaucoma industry. The market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future state of the industry.